0L49 Stock Chart & Stats
$3.68
$0.80(21.84%)
At close: 4:00 PM EDT
$3.68
$0.80(21.84%)
Day’s Range― - ―
52-Week Range$3.59 - $10.32
Previous CloseN/A
Volume11.29K
Average Volume (3M)314.00
Market Cap
$53.63M
Enterprise Value-$4.09
Total Cash (Recent Filing)$54.08M
Total Debt (Recent Filing)$1.95M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Nov 11, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding9,949,609
10 Day Avg. Volume423
30 Day Avg. Volume314
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.64
Price to Sales (P/S)1.53
P/FCF Ratio-5.98
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$17.50Price Target Upside375.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.47
Revenue Forecast (FY)$1.25M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageConservative leverage gives SCYNEXIS greater financial flexibility than a highly indebted biotech. It reduces near-term solvency pressure and leaves more capacity to fund development, partnerships, or commercialization while the company works toward sustainable profitability.
Approved Antifungal PlatformAn approved lead product provides a commercial foundation beyond a purely preclinical pipeline. SCYNEXIS also targets serious and often drug-resistant fungal infections, supporting a focused therapeutic strategy with potential for broader clinical development.
Partner-Based CommercializationA partnership-led model can provide commercialization reach without requiring a large standalone sales force. Milestones, royalties, and cost-sharing may extend market access and preserve capital, although revenue timing depends on partner execution and agreement terms.
Bears Say
Persistent Operating LossesThe return to substantial losses after stronger 2023 results indicates that profitability has not yet proved durable. Continued operating losses could constrain reinvestment, weaken equity over time, and increase dependence on financing or successful product expansion.
Negative Cash GenerationCash consumption means current operations are not self-funding, even with low balance-sheet leverage. If negative cash flow persists, SCYNEXIS may need additional capital, partnerships, or cost reductions, increasing execution risk during ongoing development and commercialization.
Potential Shareholder DilutionExpanded equity issuance capacity and warrant-related resale registration increase potential future share supply. While these actions can support funding and liquidity, issuance may dilute existing holders and create a continuing capital-markets overhang.
SCYNEXIS News
0L49 FAQ
What was SCYNEXIS’s price range in the past 12 months?
SCYNEXIS lowest share price was $3.59 and its highest was $10.32 in the past 12 months.
What is SCYNEXIS’s market cap?
SCYNEXIS’s market cap is $53.63M.
When is SCYNEXIS’s upcoming earnings report date?
SCYNEXIS’s upcoming earnings report date is Nov 11, 2026 which is in 72 days.
How were SCYNEXIS’s earnings last quarter?
SCYNEXIS released its earnings results on Aug 10, 2026. The company reported $0.63 earnings per share for the quarter, beating the consensus estimate of -$0.507 by $1.137.
Is SCYNEXIS overvalued?
According to Wall Street analysts SCYNEXIS’s price is currently Undervalued.
Does SCYNEXIS pay dividends?
SCYNEXIS does not currently pay dividends.
What is SCYNEXIS’s EPS estimate?
SCYNEXIS’s EPS estimate is -0.72.
How many shares outstanding does SCYNEXIS have?
SCYNEXIS has 9,949,609 shares outstanding.
What happened to SCYNEXIS’s price movement after its last earnings report?
SCYNEXIS reported an EPS of $0.63 in its last earnings report, beating expectations of -$0.507. Following the earnings report the stock price went down -9.528%.
Which hedge fund is a major shareholder of SCYNEXIS?
Currently, no hedge funds are holding shares in GB:0L49
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SCYNEXIS Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.50 (375.54% Upside)
$17.50 (375.54% Upside)
Blogger Sentiment
Bullish
GB:0L49 Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.82%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
23.52%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
SCYNEXIS
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
0L49 Stock 12 Month Forecast
Average Price Target
$17.50
▲(375.54% Upside)
Technical Analysis
Rockwell Med
―
TherapeuticsMD
―
Aytu BioScience
―
Cumberland Pharmaceuticals
―
IM Cannabis Corp
―